What's Happening?
AN2 Therapeutics, Inc., a biopharmaceutical company based in Menlo Park, California, announced its participation in the 2026 Stifel Virtual Targeted Oncology Forum. Eric Easom, the Co-Founder, Chairman, President, and CEO of AN2 Therapeutics, will engage
in a fireside chat during the event scheduled for May 19, 2026. The company, which focuses on developing novel small-molecule therapeutics using its boron chemistry platform, will also have management available for one-on-one meetings. AN2 Therapeutics is advancing its pipeline with three Phase 2 studies expected to be active in 2026, alongside preclinical candidates and research programs targeting oncology, bone disorders, and infectious diseases.
Why It's Important?
The participation of AN2 Therapeutics in the Stifel Virtual Targeted Oncology Forum highlights the company's commitment to advancing its research and development efforts in the biopharmaceutical sector. By focusing on novel small-molecule therapeutics, AN2 aims to address critical unmet medical needs, particularly in oncology and infectious diseases. This engagement provides an opportunity for the company to showcase its innovative approaches and potentially attract investment and partnerships that could accelerate the development and commercialization of its therapeutic candidates. The event also serves as a platform for AN2 to strengthen its presence in the competitive biopharmaceutical industry.
